
<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Tetanus Toxoid & Emerging Vaccines | Immunization Study Guide</title>
    
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">
    
    <!-- KaTeX for Math rendering -->
    <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/katex@0.16.9/dist/katex.min.css">
    <script defer src="https://cdn.jsdelivr.net/npm/katex@0.16.9/dist/katex.min.js"></script>
    <script defer src="https://cdn.jsdelivr.net/npm/katex@0.16.9/dist/contrib/auto-render.min.js" onload="renderMathInElement(document.body, {
        delimiters: [
            {left: '$$', right: '$$', display: true},
            {left: '$', right: '$', display: false}
        ]
    });"></script>
    
    <link rel="stylesheet" href="../styles/main.css">
</head>
<body>
    <a href="#main-content" class="skip-link">Skip to main content</a>
    
    <button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
        <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
        <span class="theme-toggle-icon dark-icon">üåô</span>
    </button>

    <div class="reading-progress-container">
        <div class="reading-progress-bar" id="reading-progress"></div>
    </div>

    <div class="page-wrapper">
        <div class="container">
            <article class="document-article">
                
                <!-- TOP NAVIGATION -->
                <nav class="document-nav" role="navigation" aria-label="Document Navigation">
                    <div class="nav-links">
                        <a href="topic-06-measles-rota-yf.html" class="nav-button nav-button--previous">
                            <span class="nav-icon">‚Üê</span>
                            <span class="nav-text">Previous</span>
                        </a>
                        
                        <a href="../index.html" class="nav-button">
                            <span class="nav-icon">üè†</span>
                            <span class="nav-text">Home</span>
                        </a>
                        
                        <a href="topic-08-aefi-surveillance.html" class="nav-button nav-button--next">
                            <span class="nav-text">Next</span>
                            <span class="nav-icon">‚Üí</span>
                        </a>
                    </div>
                    <div class="document-progress">
                        <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 63%;"></div>
                        </div>
                        <span class="progress-text">Topic 7 of 11</span>
                    </div>
                </nav>

                <header class="document-header">
                    <div class="header-badge">
                        <span>üõ°Ô∏è</span>
                        <span>Topic 07</span>
                    </div>
                    <h1 class="document-title">Tetanus Toxoid & Emerging Vaccines</h1>
                    <div class="title-meta">
                        <div class="meta-item">
                            <span>üìö</span>
                            <span>Clinical Protocols</span>
                        </div>
                        <div class="meta-item">
                            <span>‚è±Ô∏è</span>
                            <span>15 min read</span>
                        </div>
                    </div>
                </header>

                <main id="main-content" class="content-wrapper">
                    <!-- Section 1: TT Basics -->
                    <section class="content-section" id="tt-basics">
                        <div class="section-header">
                            <div class="section-number">01</div>
                            <h2 class="section-title">
                                <span class="title-icon">üíâ</span>
                                Tetanus Toxoid Vaccine (TT)
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>It is a relatively heat stable vaccine prepared by formalin treatment of the toxin produced by Clostridium Tetani (mainly the Harvard strain).</p>
                            <p>The most commonly used type of toxoid is the adsorbed one because the antitoxin response reaches higher titres which last longer.</p>
                            <p><strong>Note:</strong> The concentration of toxoid in the single dose adult preparations is similar to that in the paediatric preparations.</p>

                            <h3>a) Why do you give this immunization?</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">You give it to prevent tetanus disease, because there is no natural immunity to tetanus.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">TT is given regardless of age.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Pregnant women are immunized so that they provide maternal antibodies to unborn babies which protect them against neonatal tetanus-disease targeted for eradication.</span>
                                </li>
                            </ul>

                            <div class="callout callout--info">
                                <div class="callout-header">
                                    <span class="callout-icon">‚ÑπÔ∏è</span>
                                    <h4 class="callout-title">Contraindications</h4>
                                </div>
                                <div class="callout-content">
                                    <p>No known contraindications for giving TT vaccine.</p>
                                </div>
                            </div>

                            <h3>Storage and Administration</h3>
                            <div class="grid grid-2">
                                <div class="grid-item">
                                    <h4>Storage</h4>
                                    <ul>
                                        <li>Tetanus toxoid should be stored continuously at +2¬∞ C to +8¬∞ C</li>
                                        <li>Tetanus toxoid should never be frozen as this reduces its potency.</li>
                                        <li>Tetanus toxoid vaccine that has been exposed to freezing temperatures should never be used.</li>
                                    </ul>
                                </div>
                                <div class="grid-item">
                                    <h4>Administration</h4>
                                    <ul>
                                        <li>0.5 ml of the liquid is drawn into an AD syringe</li>
                                        <li>Through IM injection into the left upper arm into the deltoid muscle or non-dominant hand.</li>
                                    </ul>
                                </div>
                            </div>

                            <div class="callout callout--note">
                                <div class="callout-header">
                                    <span class="callout-icon">üìù</span>
                                    <h4 class="callout-title">Common Reactions</h4>
                                </div>
                                <div class="callout-content">
                                    <p>The main local reactions are; pain, swelling, numbness and redness at the injection site but these are usually self-limiting and do not require treatment.</p>
                                    <p>Should a person develop a severe reaction after being injected with tetanus toxoid, then the next dose must be differed until a qualified medical opinion is obtained.</p>
                                </div>
                            </div>

                            <h3>Documentation tools</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">The immunization tally sheet</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">The permanent TT Register</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">The Ante-natal Register</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">The TT injection register or booklet.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">The immunization summary sheet</span>
                                </li>
                            </ul>
                        </div>
                    </section>

                    <!-- Section 2: 5-TT Schedule -->
                    <section class="content-section" id="tt-schedules">
                        <div class="section-header">
                            <div class="section-number">02</div>
                            <h2 class="section-title">
                                <span class="title-icon">üìÖ</span>
                                5-Tetanus Toxoid Vaccination Schedule
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>The aim of the 5-TT schedule is to provide about 20 years + of protection against this killer disease for those at risk and especially for women of childbearing age and their unborn babies.</p>
                            <p>There are main opportunities for the administration of the 5-Tetanus Toxoid schedule.</p>

                            <h3>1. 5-TT FOR FOCUSED ANTENATAL CARE (FANC)</h3>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">This is given as part of Focused Antenatal Care ‚Äì FANC</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Vaccination against tetanus is given during pregnancy episodes</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Doses are documented and when a woman has received 5-doses (usually by the fourth pregnancy) no further doses should be given in subsequent pregnancies.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">After receiving 5 well spaced doses of tetanus toxoid vaccine the woman would have developed immunity for approximately 20 years, and in most cases this is long enough to cover the rest of her reproductive life.</span>
                                </li>
                            </ul>

                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <thead>
                                        <tr>
                                            <th>Pregnancy</th>
                                            <th>Dose</th>
                                            <th>Timing</th>
                                            <th>Immunity/Protection</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>First pregnancy</strong></td>
                                            <td>1st TT dose</td>
                                            <td>Given from the fourth to sixth month i.e. 2nd trimester</td>
                                            <td>Works as an immunological primer but does not confer protection against maternal tetanus at delivery. No protection from tetanus at birth!</td>
                                        </tr>
                                        <tr>
                                            <td></td>
                                            <td>2nd TT dose</td>
                                            <td>Given one month after the 1st dose (between the fifth & eighth month)</td>
                                            <td>Confers protection from maternal tetanus at delivery & for about 1 ‚Äì 3 years from tetanus in general. Confers protection at birth (PAB) for ‚â•90% of neonates.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Second pregnancy</strong></td>
                                            <td>3rd TT dose</td>
                                            <td>Given anytime between the forth & eighth months</td>
                                            <td>Immunity boosted for 5 years</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Third Pregnancy</strong></td>
                                            <td>4th TT dose</td>
                                            <td>Given anytime between the fourth & eighth month</td>
                                            <td>Immunity boosted for 10 years</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Fourth pregnancy</strong></td>
                                            <td>5th TT & last dose</td>
                                            <td>Given anytime between the fourth & eighth month</td>
                                            <td>Immunity boosted for 20 years</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Subsequent pregnancies</strong></td>
                                            <td>No more TT doses</td>
                                            <td>-</td>
                                            <td>Immunity adequate for rest of parous life</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>

                            <details class="collapsible-section">
                                <summary class="collapsible-trigger">
                                    <span class="trigger-icon">‚ñ∂</span>
                                    <span class="trigger-text">Other TT Schedules (WRA, Trauma, School)</span>
                                </summary>
                                <div class="collapsible-content">
                                    <h4>5-TT For GIRLS AND WOMEN OF CHILD BEARING AGE (CBAWS)</h4>
                                    <p>Tetanus toxoid vaccination is given to females aged between 15 to 49 years irrespective of their pregnancy status or reproductive health goals</p>
                                    <ul>
                                        <li>The lower and upper age limits can be varied according to local experience of childbearing patterns.</li>
                                        <li>This schedule builds up the immunity of the girl or woman for the assumed eventuality of pregnancy and childbirth for herself and her future babies.</li>
                                    </ul>

                                    <h4>5-TT for Trauma and Occupational prophylaxis</h4>
                                    <p>This schedule is usually initiated in the event of trauma and the tetanus toxoid doses should be given in the prescribed intervals until all 5 doses have been given. After the five doses, recipients would have acquired immunity against tetanus for 20 years.</p>
                                    
                                    <div class="table-responsive">
                                        <table class="content-table content-table--compact">
                                            <thead>
                                                <tr>
                                                    <th>Dose</th>
                                                    <th>Timing</th>
                                                    <th>Duration of Immunity</th>
                                                </tr>
                                            </thead>
                                            <tbody>
                                                <tr>
                                                    <td>1st TT dose</td>
                                                    <td>At 1st contact or at least within seven days of the injury</td>
                                                    <td>None (priming)</td>
                                                </tr>
                                                <tr>
                                                    <td>2nd TT dose</td>
                                                    <td>One month after 1st TT</td>
                                                    <td>1-2 Years protection</td>
                                                </tr>
                                                <tr>
                                                    <td>3rd TT dose</td>
                                                    <td>Six months after 2nd TT</td>
                                                    <td>3 Years protection</td>
                                                </tr>
                                                <tr>
                                                    <td>4th TT dose</td>
                                                    <td>One year after 3rd TT</td>
                                                    <td>10 years protection</td>
                                                </tr>
                                                <tr>
                                                    <td>5th TT dose</td>
                                                    <td>One year after 4th TT</td>
                                                    <td>20 Years protection</td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </div>

                                    <h4>5-TT schedule for school-aged children</h4>
                                    <p>A special programme restricted to the districts of coast province.</p>
                                </div>
                            </details>
                        </div>
                    </section>

                    <!-- Section 3: Non-KEPI & Emerging -->
                    <section class="content-section" id="emerging-vaccines">
                        <div class="section-header">
                            <div class="section-number">03</div>
                            <h2 class="section-title">
                                <span class="title-icon">üÜï</span>
                                Non-KEPI & Emerging Vaccines
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>NON-KEPI VACCINES</h3>
                            <p>Cholera, typhoid, HePatitisA, B&C, Rabies, Snake, influenza-H5N1, H1N1, Varicella-chiken pox, HPV</p>

                            <h3>NEW & EMERGING VACCINES</h3>
                            
                            <h4>Malaria vaccine</h4>
                            <ol class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Current clinical studies have shown that new candidate vaccines can induce complete protection against malaria infection.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Complete protection against malaria can be induced by infecting volunteers with irradiated malaria parasites.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">People living in endemic areas who have had multiple exposures to malaria develop immunity against severe malaria disease.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Since antibodies are unable to attack the malaria parasite once it has invaded liver cells, new approaches to the malaria vaccine development have been to design a vaccine that will induce potent T-cell responses against the liver stage of malaria infection.</span>
                                </li>
                            </ol>
                            <p>Preliminary Phase III clinical trial results for RTS,S/AS01 malaria vaccine indicate that it is about 50% efficacious with a protection of 12 months. It is a Pre-erythrocytic stage vaccine candidate (liver stage).</p>

                            <h4>HIV vaccine</h4>
                            <p>Currently, there is no licensed vaccine to protect against HIV/AIDS. The preventive AIDS vaccines currently in human trials do not contain any live virus that could result in infection and thus cannot cause HIV/AIDS. These vaccine candidates are recombinant vaccines that use genetically engineered components of HIV.</p>
                            
                            <div class="callout callout--note">
                                <div class="callout-header">
                                    <span class="callout-icon">üí°</span>
                                    <h4 class="callout-title">Potential Impact</h4>
                                </div>
                                <div class="callout-content">
                                    <p>An AIDS Vaccine would make a difference by:</p>
                                    <ul>
                                        <li>protecting vaccinated individuals against HIV infection</li>
                                        <li>reducing the probability that a vaccinated individual who later becomes infected will transmit the infection to others; or</li>
                                        <li>slowing the rate of progression to AIDS for those who later become infected with HIV.</li>
                                    </ul>
                                </div>
                            </div>
                        </div>
                    </section>

                    <!-- Key Points Section -->
                    <aside class="key-points-section" role="region" aria-labelledby="key-points-title">
                        <div class="key-points-wrapper">
                            <div class="key-points-header">
                                <span class="key-points-icon">‚≠ê</span>
                                <h3 id="key-points-title" class="key-points-title">Key Points</h3>
                            </div>
                            <ul class="key-points-list">
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>The 5-TT schedule aims to provide immunity against tetanus for approximately 20 years.</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>The 1st TT dose in pregnancy (or trauma) is an immunological primer and does not confer protection.</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Tetanus Toxoid should never be frozen as this reduces its potency.</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>RTS,S/AS01 is a pre-erythrocytic stage malaria vaccine candidate with about 50% efficacy.</strong></p>
                                </li>
                            </ul>
                        </div>
                    </aside>
                </main>

                <!-- BOTTOM NAVIGATION -->
                <nav class="document-nav" role="navigation" aria-label="Document Navigation">
                    <div class="nav-links">
                        <a href="topic-06-measles-rota-yf.html" class="nav-button nav-button--previous">
                            <span class="nav-icon">‚Üê</span>
                            <span class="nav-text">Previous</span>
                        </a>
                        
                        <a href="../index.html" class="nav-button">
                            <span class="nav-icon">üè†</span>
                            <span class="nav-text">Home</span>
                        </a>
                        
                        <a href="topic-08-aefi-surveillance.html" class="nav-button nav-button--next">
                            <span class="nav-text">Next</span>
                            <span class="nav-icon">‚Üí</span>
                        </a>
                    </div>
                    <div class="document-progress">
                        <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 63%;"></div>
                        </div>
                        <span class="progress-text">Topic 7 of 11</span>
                    </div>
                </nav>

            </article>
        </div>
    </div>

    <!-- Lightbox Modal -->
    <div id="lightbox" class="lightbox-modal" hidden aria-hidden="true" role="dialog" aria-label="Image viewer">
        <div class="lightbox-backdrop" data-close-lightbox></div>
        <div class="lightbox-content">
            <button class="lightbox-close" data-close-lightbox aria-label="Close image viewer">&times;</button>
            <img src="" alt="" class="lightbox-image" id="lightbox-img">
            <p class="lightbox-caption" id="lightbox-caption"></p>
        </div>
    </div>

    <script src="../js/theme.js"></script>
    <script src="../js/navigation.js"></script>
    <script src="../js/interactions.js"></script>
</body>
</html>